CLDX Stock Analysis: Buy, Sell, or Hold?
CLDX - Celldex Therapeutics, Inc
$40.38
0.44 (1.10%)
â˛
5d:
-3.74%
30d:
+14.0%
90d:
+32.05%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CLDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLDX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLDX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLDX is currently trading at $40.38, which is considered slightly high relative to its 30-day fair value range of $36.05 to $42.06.
Technical Outlook: Technically, CLDX is in a strong uptrend. The price is currently testing key support at $39.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CLDX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.07 (+43.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLDX is in a strong uptrend. The price is currently testing key support at $39.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CLDX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.07 (+43.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$36.05 -
$42.06
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.8% below Wall St target ($58.07)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$36.05 -
$42.06
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$39.45
Resistance Level
$45.14
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.70
Wall Street Target
$58.07
(+43.8%)
Revenue Growth (YoY)
-97.0%
Share & Embed Analysis
Last updated: August 22, 2026 11:49 AM ET
Data refreshes hourly during market hours. Next update: 12:49 PM
Data refreshes hourly during market hours. Next update: 12:49 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
